Alzamend Neuro Inc (ALZN)vsModerna Inc (MRNA)
ALZN
Alzamend Neuro Inc
$1.72
+1.18%
HEALTHCARE · Cap: $8.20M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
ALZN leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
ALZN
Avoid20
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALZN.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 10.1x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALZN
ALZN has a balanced fundamental profile.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ALZN
The primary concerns for ALZN are Price/Book, Revenue Growth, EPS Growth.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ALZN profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ALZN generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 20/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alzamend Neuro Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alzamend Neuro Inc. is an innovative biotechnology company poised to revolutionize the treatment landscape for neurodegenerative diseases, especially Alzheimer's disease. Utilizing a proprietary drug development platform and a robust intellectual property portfolio, the company is strategically positioned to meet significant unmet medical needs in the pharmaceutical market. With a commitment to advancing its therapeutic candidates through rigorous clinical trials and fostering strategic partnerships, Alzamend Neuro aims to enhance patient quality of life and make substantial contributions to the neurotherapeutics sector. Its focused approach on critical neurological health challenges presents a compelling investment opportunity within the biotech industry.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?